Skip to main content

Advertisement

Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Soluble Siglec-9 suppresses arthritis in a collagen-induced arthritis mouse model and inhibits M1 activation of RAW264.7 macrophages

Fig. 1

Effects of soluble sialic acid-binding immunoglobulin-type lectin (sSiglec)-9 on arthritis symptoms in mice with collagen-induced arthritis (CIA). a Postinjection (24 h, non-CIA versus CIA) images with VivoTag 680 XL-labeled sSiglec-9. Accumulation of fluorescence in CIA joints is denoted by dashed red circles. b Representative images of hind paws from each treatment group. c Cumulative incidence of arthritis in control CIA mice (untreated) and mice treated with different dosages of sSiglec-9. *p < 0.05 for sSiglec-9 50 ng/g versus control (χ2 test). d Severity of arthritis symptoms as evaluated using the arthritis score in control CIA mice (untreated) and mice treated with different dosages of soluble sSiglec-9. *p < 0.05 for sSiglec-9 50 ng/g versus control (Bonferroni post hoc test). e Serum tumor necrosis factor (TNF)-α concentration was significantly decreased in mice treated with 50 mg/g sSiglec-9. *p < 0.05 (Bonferroni post hoc test). f Arthritis score and serum TNF-α concentration were strongly and positively correlated (p < 0.01, R = 0.837 [Pearson product-moment correlation coefficient])

Back to article page